Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 from 8:00–8:25 AM GMT (4:00–4:25 AM ET). The presentation will be webcast and available under Events and Presentations in the Investors section at www.candeltx.com. A replay will be archived for up to 90 days after the session.
Candel Therapeutics (Nasdaq: CADL) announced the appointment of Bali Pulendran, Ph.D. to its Research Advisory Board on October 16, 2025. Dr. Pulendran is a systems immunology and vaccinology expert, Violetta L. Horton Professor at Stanford, Director of the Institute for Immunity, Transplantation and Infection, and a Thomson Reuters Highly Cited Researcher.
He will advise as Candel advances lead viral immunotherapy candidates CAN-2409 across multiple solid tumors and CAN-3110 for recurrent high-grade glioma, bringing expertise in dendritic cell biology and human immune-response systems.
Candel Therapeutics (Nasdaq: CADL) entered a five-year $130 million term loan facility with Trinity Capital on Oct 14, 2025, with $50 million drawn at closing and access to up to an additional $80 million across three tranches.
The facility carries an initial interest option of 10.25% per annum, a 36-month interest-only period (extendable 12 months upon a commercial milestone), and contains customary covenants and events of default. Candel reported $87.2 million cash as of Sept 30, 2025. Proceeds will refinance an existing loan and fund working capital, initiation of a pivotal phase 3 CAN-2409 NSCLC trial planned for Q2 2026, and prepare for a potential BLA submission in prostate cancer in Q4 2026.
Trinity Capital (Nasdaq: TRIN) committed $130 million in growth capital to Candel Therapeutics (Nasdaq: CADL) on October 14, 2025 to support development of viral immunotherapies.
The funding is earmarked to support clinical development of CAN-2409 and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer pending regulatory approval. Candel's pipeline includes CAN-2409 and CAN-3110 targeting solid tumors (prostate, pancreatic, lung, brain).
Candel has received multiple FDA designations: RMAT for localized prostate cancer, Fast Track for localized prostate and non-small cell lung cancer, and dual Fast Track and Orphan Drug designations for pancreatic and brain cancer programs.
Candel Therapeutics (Nasdaq: CADL) reported encouraging interim phase 1b data for CAN-3110 in recurrent glioblastoma and a related Science Translational Medicine publication on October 8, 2025. Serial multiomic analysis of 97 tumor biopsies from two patients after repeated CAN-3110 dosing showed tumor-to-immune-cell replacement and one complete pathological response despite MRI increases that can mimic progression. Investigators observed expansion of tissue-resident effector memory T cell clonotypes and HLA-presented tumor and viral peptides, supporting viral- and tumor-specific immune activation. Updated median overall survival was 11.8 months (arm A, n=41) and 12.0 months (arm B, n=9). Arm C (n=9) had multiple administrations; no clear benefit beyond 4 injections was seen.
Candel Therapeutics (Nasdaq: CADL) announced it will present multiple updates at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5-9, 2025, National Harbor, Maryland. The company will present two poster abstracts on Nov 7: one on its enLIGHTEN Discovery Platform and one on CAN-2409+valacyclovir immune responses in NSCLC. CEO Dr. Paul Peter Tak will give an invited faculty presentation and participate in a panel to present positive phase 3 CAN-2409 data in localized prostate cancer on Nov 7 at 3:55–5:35 p.m.
Candel Therapeutics (Nasdaq: CADL) presented positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer at ASTRO 2025. The trial, involving 745 patients with intermediate-to-high-risk localized prostate cancer, demonstrated a 30% improvement in disease-free survival (HR 0.7, p=0.0155) and 38% improvement in prostate cancer-specific disease-free survival (HR 0.62, p=0.0046).
Key findings showed CAN-2409's efficacy was consistent across radiation therapy modalities, with significant improvements observed in both moderate hypofractionated EBRT (HR 0.52) and conventional EBRT (HR 0.76). The treatment achieved 80.4% pathological complete response rates compared to 63.6% in the control arm. Grade ≥3 treatment-related adverse events remained similar between treatment and control groups.
The company plans to submit a Biologics License Application in Q4 2026, positioning CAN-2409 as potentially the first major advancement in localized prostate cancer treatment in over 20 years.
Candel Therapeutics (NASDAQ:CADL) announced the acceptance of their abstract for oral presentation at the 2025 ASTRO Annual Meeting in San Francisco. The presentation will showcase results from their Phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer.
Dr. Glen Gejerman from Hackensack University Medical Center will present the findings of the randomized, placebo-controlled study evaluating CAN-2409+Prodrug in combination with standard EBRT for newly diagnosed localized prostate cancer. The presentation is scheduled for September 28, 2025, at 2:30 PM PT. The abstract has also been selected for ASTRO's Science Highlights - Genitourinary Cancer session.
Candel Therapeutics (Nasdaq: CADL) has appointed renowned immunotherapy pioneer Dr. Carl H. June to its Research Advisory Board. Dr. June, known for developing the first FDA-approved CAR-T cell therapy, will support Candel's advancement of its viral immunotherapy candidates.
Dr. June currently serves as the Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania's Perelman School of Medicine and directs both the Center for Cellular Immunotherapies and Parker Institute for Cancer Immunotherapy. The appointment comes as Candel prepares for a planned BLA submission for CAN-2409 in prostate cancer during Q4 2026.
Candel Therapeutics (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing biological immunotherapies for cancer treatment, announced its participation in three major investor conferences in September 2025.
The company's President and CEO, Dr. Paul Peter Tak, will present at the Citi Biopharma Back to School Conference (September 3), the Cantor Global Healthcare Conference (September 4), and the H.C. Wainwright Global Investment Conference (September 5). All presentations will be available via webcast on the company's website, with replays accessible for up to 90 days.